Blue Trust Inc’s Inovio Pharmaceuticals INO Stock Holding History

Blue Trust Inc’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-19	Closed	–	–	2275
2023 Q1	$0	Buy	+19	New	+$324	﹤0.01%	2466

Other funds holding INO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Blue Trust Inc's INO Position: Q2 2023 in Review

Blue Trust Inc sold out of Inovio Pharmaceuticals (INO) in Q2 2023, closing a stake of 19 shares.

Blue Trust Inc first reported a position in INO in Q1 2023 and held it in 1 quarter. The position peaked at $0 in Q1 2023. 133 funds tracked by Wall St. Rank hold INO as of Q2 2023.

Blue Trust Inc reported no remaining Inovio Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Blue Trust Inc sold 19 Inovio Pharmaceuticals shares in Q2 2023.
Blue Trust Inc first reported a position in Inovio Pharmaceuticals in Q1 2023 and held it in 1 quarter.
Blue Trust Inc's Inovio Pharmaceuticals position peaked at $0 in Q1 2023.
133 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2023.

Based on Blue Trust Inc's 13F filing for Q2 2023, filed 14 Jul 2023.